Beyond Obesity: The Diagnosis and Pathophysiology of Metabolic Syndrome
American Society for Clinical Laboratory Science · 2010-01 · 23 (1) · 51-61
DOI: 10.29074/ascls.23.1.51 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Society for Clinical Laboratory Science, online erschienen am 01.01.2010. Verfasst von Wayne Gade und 3 weiteren Autor:innen. Die Arbeit wurde bisher 79-mal zitiert (Crossref).
Abstract (Originalsprache)
Metabolic syndrome (MSX) identifies clinical symptoms and lab results, including abdominal obesity, insulin resistance, hyperglycemia, hyperlipidemia, and hypertension, that lead to an increased risk of cardiovascular disease (CVD). Obesity typically results in insulin and leptin resistance and a shift from expansion of subcutaneous fat to deposition of abdominal and ectopic fat. These conditions cause metabolic dysregulation, elevated fatty acids (FFA), and increased secretion of pro-inflammatory "adipokines". Left untreated, these conditions cause lipotoxicity, chronic inflammation, hypertension, atherosclerosis, and CVD.
Zitieren
APA
Gade, W., Schmit, J., Collins, M., & Gade, J. (2010). Beyond Obesity: The Diagnosis and Pathophysiology of Metabolic Syndrome. American Society for Clinical Laboratory Science, 23(1), 51-61. https://doi.org/10.29074/ascls.23.1.51
Vancouver
Gade W, Schmit J, Collins M, Gade J. Beyond Obesity: The Diagnosis and Pathophysiology of Metabolic Syndrome. American Society for Clinical Laboratory Science. 2010;23(1):51-61. doi:10.29074/ascls.23.1.51
BibTeX
@article{Gade2010,
author = {Gade, Wayne and Schmit, Jessica and Collins, Melissa and Gade, Jean},
title = {Beyond Obesity: The Diagnosis and Pathophysiology of Metabolic Syndrome},
journal = {American Society for Clinical Laboratory Science},
year = {2010},
volume = {23},
number = {1},
pages = {51--61},
doi = {10.29074/ascls.23.1.51}
}
EUVIMED